Epilepsy Archives

News and Trends 1 Jun 2022

New treatment option available for Dravet syndrome

Global biopharma company UCB says the UK’s National Institute for Healthcare Excellence (NICE) has issued a positive Final Appraisal Determination (FAD) for its FINTEPLA (fenfluramine) oral solution. FINTEPLA is used for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other anti-epileptic medicines for patients two years of age and older. […]

June 1, 2022 - 3 minutesmins - By Jim Cornall

central nervous system epilepsy parkinsons disease

News and Trends 29 May 2020

Spanish Neurology Biotech Launches with €7.6M Series A

Accure Therapeutics, a neurology biotech targeting central nervous system (CNS) conditions such as multiple sclerosis and Parkinson’s disease, has launched in Barcelona with a Series A of €7.6M. Alta Life Sciences, a life science venture capital firm based in the same city, and the Spanish governmental institution The Centre for Technological and Industrial Development funded […]

May 29, 2020 - 3 minutesmins - By Helen Albert

arvelle therapeutics SK Biopharmaceuticals Axovant epilepsy

More News! 18 Feb 2019

Enormous Series A to Help Bring Epilepsy Drug to Market

One of the biggest Series A rounds in European biotech, €159M ($180M), has been raised by the Swiss company Arvelle Therapeutics to help commercialize its epilepsy drug. Formed just this month, Arvelle plans to submit an application for EMA approval for the small molecule drug cenobamate, which it has licensed from the South Korean company […]

February 18, 2019 - 2 minutesmins - By Jonathan Smith

More News! 8 Oct 2018

Cannabinoid Drugs Company Raises $300M in Public Offering

GW Pharmaceuticals, a British biotech developing cannabinoid drugs, is on a high after a successful $300M public offering on the Nasdaq Stock Market. The company announced the public offering swiftly after its lead cannabinoid drug, Epidiolex, made history by being the first cannabinoid drug to obtain approval from the FDA earlier this year. GW plans […]

October 8, 2018 - 2 minutesmins - By Jonathan Smith

gw pharmaceuticals fda epidiolex cannabinoid epilepsy

News and Trends 26 Jun 2018

Update: The FDA Approves First Cannabinoid Treatment for Epilepsy

Update (26/06/2018): The FDA has approved GW Pharmaceutical’s drug Epidiolex in two severe forms of epilepsy. The approval makes Epidolex the first prescription drug made from highly purified cannabidiol to reach the market. Published on 20/04/2018 GW Pharmaceuticals has received a unanimous recommendation from the FDA Advisory Committee Meeting supporting the approval of what could soon […]

June 26, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Feb 2018

GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II

One of GW Pharma’s cannabinoid drugs for epilepsy has suffered a set back in a Phase IIa trial as a placebo matched its capacity to reduce the frequency of focal seizures. GW Pharma wants to use cannabinoid drugs to treat conditions like autism and epilepsy. However, one of its drug candidates, GWP42006, has slipped up in a Phase […]

February 22, 2018 - 2 minutesmins - By Alex Dale

News and Trends 25 Jan 2018

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […]

January 25, 2018 - 3 minutesmins - By Alex Dale

News and Trends 12 Jan 2018

This Collaboration Will Develop a New Epilepsy Gene Therapy for In-Need Patients

CombiGene and the Cell and Gene Therapy Catapult have struck a deal that will move the biotech’s epilepsy therapy towards the clinic. Swedish biotech CombiGene has combined neuroscience and advances in gene delivery to pioneer and new therapy for epilepsy that has brought down the number of seizures in preclinical studies. The company has joined forces […]

January 12, 2018 - 2 minutesmins - By Alex Dale

News and Trends 15 Dec 2017

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

GW Pharma might be about to join the likes of Genmab in the biotech blockbuster club, with its epilepsy drug predicted to achieve sales of close to $1B in 2018. GW Pharma develops therapies for a range of diseases, including autism, epilepsy and brain cancer using its cannabinoid product platform. In a rundown of the top 10 […]

December 15, 2017 - 2 minutesmins - By Alex Dale

More News! 9 Aug 2017

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

Zynerba Pharmaceuticals cannabinoid drug for epilepsy missed all of its endpoints costing the company’s stock price more than 55% — and GW Pharma 8.6%. On Monday, Zynerba Pharmaceuticals, a Pennsylvania-based biotech, announced that its transdermal cannabinoid candidate ZYN002 for refractory epilepsy with focal seizures had not met any of its endpoints in a Phase II […]

August 9, 2017 - 2 minutesmins - By Evelyn Warner

cannabidiol cannabis epilepsy davet syndrome epidiolex gw pharmaceuticals cbd

News and Trends 26 May 2017

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

UPDATE (26/05/2017): GW has released more positive results in The New England Journal of Medicine demonstrating that Epidiolex dramatically reduces convulsive seizures in children with Dravet syndrome. The results have primed the drug for its NDA submission to the FDA and led some to forecast blockbuster success. Original Publication 30/03/2016 GW Pharmaceuticals (UK) has announced positive results […]

May 26, 2017 - 4 minutesmins - By Ekaterina Perets

More News! 29 Mar 2017

More “FDA Love” for Cannabis Company with Orphan Drug Designation

Last year was a doozy for biotech, but it was spectacular for GW Pharmaceuticals. Its streak continues with more special treatment. GW Pharmaceuticals, which is developing epilepsy treatments from marijuana, is making a name for itself not just as “that company” turning a recreational drug into medical ones; the company was also one of 2016’s surprise successes — its […]

March 29, 2017 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Epilepsy

New treatment option available for Dravet syndrome

Spanish Neurology Biotech Launches with €7.6M Series A

Enormous Series A to Help Bring Epilepsy Drug to Market

Cannabinoid Drugs Company Raises $300M in Public Offering

Update: The FDA Approves First Cannabinoid Treatment for Epilepsy

GW Pharma’s Latest Cannabinoid Drug Pegged Back by a Placebo in Phase II

Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy

This Collaboration Will Develop a New Epilepsy Gene Therapy for In-Need Patients

Signed, Sealed. Will GW Pharma’s Epilepsy Treatment Be a 2018 Blockbuster?

UK Cannabinoid Company Loses 9% and a Competitor after American Phase II Failure

UPDATE: UK Cannabis Biotech ready for a Blockbuster in Rare Epilepsy

More “FDA Love” for Cannabis Company with Orphan Drug Designation

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!